The Experts below are selected from a list of 40545 Experts worldwide ranked by ideXlab platform

Jeanlouis Lefaix - One of the best experts on this subject based on the ideXlab platform.

  • complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline tocopherol clodronate combination pentoclo a phase ii trial
    International Journal of Radiation Oncology Biology Physics, 2011
    Co-Authors: Sylvie Delanian, J Depondt, Cecile Chatel, Raphael Porcher, Jeanlouis Lefaix
    Abstract:

    Purpose Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic Evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive—(f[t] = a.exp(-b.t)—and significant ( p 2 −42%, D 4 −62%, D 6 −77%, D 12 −92%, and D 18 −96%, combined with iterative spontaneous sequestrectomies in 36 patients. All patients experienced complete recovery in a median of 9 months. Clinical improvement was measured in terms of discontinuation of analgesics, new fracture, closed skin fistulae, and delayed radiologic improvement: SOMA 6 −64%, SOMA 12 −89%, and SOMA 30 −96%. Conclusion Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.

  • complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline tocopherol clodronate combination pentoclo a phase ii trial
    International Journal of Radiation Oncology Biology Physics, 2011
    Co-Authors: Sylvie Delanian, J Depondt, Cecile Chatel, Raphael Porcher, Jeanlouis Lefaix
    Abstract:

    Purpose Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic Evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive--(f[t] = a.exp(-b.t)--and significant (p Conclusion Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.

  • major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol a phase ii trial
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2005
    Co-Authors: Sylvie Delanian, J Depondt, Jeanlouis Lefaix
    Abstract:

    BACKGROUND: Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Is a treatment combining pentoxifylline (PTX) and tocopherol (vitamin E) boosted by clodronate effective in reversing this fibronecrotic process? METHODS: Eighteen consecutive patients previously irradiated for head and neck cancer had exteriorized mandible ORN. Length of exposed bone (L) was 13.4 +/- 8 mm, and the mean subjective objective medical management and Analytic Evaluation of injury (SOMA) score was 12.6 +/- 4.9. Between June 1995 and January 2002, all 18 were given a daily oral combination of 800 mg of PTX and 1000 IU of vitamin E for 6 to 24 months. In addition, the last eight patients who were the worst cases were given 1600 mg/day clodronate 5 days a week. RESULTS: The treatment was well tolerated. All patients improved at 6 months, with 84% mean L and 67% mean SOMA score reductions. Sixteen (89%) of 18 patients achieved complete recovery, 14 in 5 +/- 2.6 months. The remaining two patients exhibited a 75% response at 6 months. CONCLUSION: PTX-vitamin E boosted by clodronate is an effective treatment of mandibular ORN that induces mucosal and bone healing in a median period of 6 months.

Sylvie Delanian - One of the best experts on this subject based on the ideXlab platform.

  • complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline tocopherol clodronate combination pentoclo a phase ii trial
    International Journal of Radiation Oncology Biology Physics, 2011
    Co-Authors: Sylvie Delanian, J Depondt, Cecile Chatel, Raphael Porcher, Jeanlouis Lefaix
    Abstract:

    Purpose Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic Evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive—(f[t] = a.exp(-b.t)—and significant ( p 2 −42%, D 4 −62%, D 6 −77%, D 12 −92%, and D 18 −96%, combined with iterative spontaneous sequestrectomies in 36 patients. All patients experienced complete recovery in a median of 9 months. Clinical improvement was measured in terms of discontinuation of analgesics, new fracture, closed skin fistulae, and delayed radiologic improvement: SOMA 6 −64%, SOMA 12 −89%, and SOMA 30 −96%. Conclusion Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.

  • complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline tocopherol clodronate combination pentoclo a phase ii trial
    International Journal of Radiation Oncology Biology Physics, 2011
    Co-Authors: Sylvie Delanian, J Depondt, Cecile Chatel, Raphael Porcher, Jeanlouis Lefaix
    Abstract:

    Purpose Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic Evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive--(f[t] = a.exp(-b.t)--and significant (p Conclusion Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.

  • major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol a phase ii trial
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2005
    Co-Authors: Sylvie Delanian, J Depondt, Jeanlouis Lefaix
    Abstract:

    BACKGROUND: Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Is a treatment combining pentoxifylline (PTX) and tocopherol (vitamin E) boosted by clodronate effective in reversing this fibronecrotic process? METHODS: Eighteen consecutive patients previously irradiated for head and neck cancer had exteriorized mandible ORN. Length of exposed bone (L) was 13.4 +/- 8 mm, and the mean subjective objective medical management and Analytic Evaluation of injury (SOMA) score was 12.6 +/- 4.9. Between June 1995 and January 2002, all 18 were given a daily oral combination of 800 mg of PTX and 1000 IU of vitamin E for 6 to 24 months. In addition, the last eight patients who were the worst cases were given 1600 mg/day clodronate 5 days a week. RESULTS: The treatment was well tolerated. All patients improved at 6 months, with 84% mean L and 67% mean SOMA score reductions. Sixteen (89%) of 18 patients achieved complete recovery, 14 in 5 +/- 2.6 months. The remaining two patients exhibited a 75% response at 6 months. CONCLUSION: PTX-vitamin E boosted by clodronate is an effective treatment of mandibular ORN that induces mucosal and bone healing in a median period of 6 months.

J Depondt - One of the best experts on this subject based on the ideXlab platform.

  • complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline tocopherol clodronate combination pentoclo a phase ii trial
    International Journal of Radiation Oncology Biology Physics, 2011
    Co-Authors: Sylvie Delanian, J Depondt, Cecile Chatel, Raphael Porcher, Jeanlouis Lefaix
    Abstract:

    Purpose Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic Evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive—(f[t] = a.exp(-b.t)—and significant ( p 2 −42%, D 4 −62%, D 6 −77%, D 12 −92%, and D 18 −96%, combined with iterative spontaneous sequestrectomies in 36 patients. All patients experienced complete recovery in a median of 9 months. Clinical improvement was measured in terms of discontinuation of analgesics, new fracture, closed skin fistulae, and delayed radiologic improvement: SOMA 6 −64%, SOMA 12 −89%, and SOMA 30 −96%. Conclusion Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.

  • complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline tocopherol clodronate combination pentoclo a phase ii trial
    International Journal of Radiation Oncology Biology Physics, 2011
    Co-Authors: Sylvie Delanian, J Depondt, Cecile Chatel, Raphael Porcher, Jeanlouis Lefaix
    Abstract:

    Purpose Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? Methods 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic Evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. Results Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive--(f[t] = a.exp(-b.t)--and significant (p Conclusion Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.

  • major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol a phase ii trial
    Head and Neck-journal for The Sciences and Specialties of The Head and Neck, 2005
    Co-Authors: Sylvie Delanian, J Depondt, Jeanlouis Lefaix
    Abstract:

    BACKGROUND: Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Is a treatment combining pentoxifylline (PTX) and tocopherol (vitamin E) boosted by clodronate effective in reversing this fibronecrotic process? METHODS: Eighteen consecutive patients previously irradiated for head and neck cancer had exteriorized mandible ORN. Length of exposed bone (L) was 13.4 +/- 8 mm, and the mean subjective objective medical management and Analytic Evaluation of injury (SOMA) score was 12.6 +/- 4.9. Between June 1995 and January 2002, all 18 were given a daily oral combination of 800 mg of PTX and 1000 IU of vitamin E for 6 to 24 months. In addition, the last eight patients who were the worst cases were given 1600 mg/day clodronate 5 days a week. RESULTS: The treatment was well tolerated. All patients improved at 6 months, with 84% mean L and 67% mean SOMA score reductions. Sixteen (89%) of 18 patients achieved complete recovery, 14 in 5 +/- 2.6 months. The remaining two patients exhibited a 75% response at 6 months. CONCLUSION: PTX-vitamin E boosted by clodronate is an effective treatment of mandibular ORN that induces mucosal and bone healing in a median period of 6 months.

Jurgen Gauss - One of the best experts on this subject based on the ideXlab platform.

  • communication spin densities within a unitary group based spin adapted open shell coupled cluster theory Analytic Evaluation of isotropic hyperfine coupling constants for the combinatoric open shell coupled cluster scheme
    Journal of Chemical Physics, 2015
    Co-Authors: Dipayan Datta, Jurgen Gauss
    Abstract:

    We report Analytical calculations of isotropic hyperfine-coupling constants in radicals using a spin-adapted open-shell coupled-cluster theory, namely, the unitary group based combinatoric open-shell coupled-cluster (COSCC) approach within the singles and doubles approximation. A scheme for the Evaluation of the one-particle spin-density matrix required in these calculations is outlined within the spin-free formulation of the COSCC approach. In this scheme, the one-particle spin-density matrix for an open-shell state with spin S and MS = + S is expressed in terms of the one- and two-particle spin-free (charge) density matrices obtained from the Lagrangian formulation that is used for calculating the Analytic first derivatives of the energy. Benchmark calculations are presented for NO, NCO, CH2CN, and two conjugated π-radicals, viz., allyl and 1-pyrrolyl in order to demonstrate the performance of the proposed scheme.

  • Analytic second derivatives for the spin free exact two component theory
    Journal of Chemical Physics, 2011
    Co-Authors: Lan Cheng, Jurgen Gauss
    Abstract:

    The formulation and implementation of the spin-free (SF) exact two-component (X2c) theory at the one-electron level (SFX2c-1e) is extended in the present work to the Analytic Evaluation of second derivatives of the energy. In the X2c-1e scheme, the four-component one-electron Dirac Hamiltonian is block diagonalized in its matrix representation and the resulting “electrons-only” two-component Hamiltonian is then used together with untransformed two-electron interactions. The derivatives of the two-component Hamiltonian can thus be obtained by means of simple manipulations of the parent four-component Hamiltonian integrals and derivative integrals. The SF version of X2c-1e can furthermore exploit available nonrelativistic quantum-chemical codes in a straightforward manner. As a first application of Analytic SFX2c-1e second derivatives, we report a systematic study of the equilibrium geometry and vibrational frequencies for the bent ground state of the copper hydroxide (CuOH) molecule. Scalar-relativistic, e...

Georgios B Giannakis - One of the best experts on this subject based on the ideXlab platform.

  • linear constellation precoding for ofdm with maximum multipath diversity and coding gains
    IEEE Transactions on Communications, 2003
    Co-Authors: Zhiqiang Liu, Yan Xin, Georgios B Giannakis
    Abstract:

    Orthogonal frequency-division multiplexing (OFDM) converts a frequency-selective fading channel into parallel flat-fading subchannels, thereby simplifying channel equalization and symbol decoding. However, OFDM's performance suffers from the loss of multipath diversity, and the inability to guarantee symbol detectability when channel nulls occur. We introduce a linear constellation precoded OFDM for wireless transmissions over frequency-selective fading channels. Exploiting the correlation structure of subchannels and choosing system parameters properly, we first perform an optimal subcarrier grouping to divide the set of subchannels into subsets. Within each subset, a linear constellation-specific precoder is then designed to maximize both diversity and coding gains. While greatly reducing the decoding complexity and simplifying the precoder design, subcarrier grouping enables the maximum possible diversity and coding gains. In addition to reduced complexity, the proposed system guarantees symbol detectability regardless of channel nulls, and does not reduce the transmission rate. Analytic Evaluation and corroborating simulations reveal its performance merits.

  • linear constellation precoding for ofdm with maximum multipath diversity and coding gains
    Asilomar Conference on Signals Systems and Computers, 2001
    Co-Authors: Zhiqiang Liu, Yan Xin, Georgios B Giannakis
    Abstract:

    This paper introduces linear constellation precoding (LCP) for OFDM transmissions over frequency-selective fading channels. Exploiting the correlation structure of OFDM subchannels, and choosing system parameters properly, we first perform optimal subcarrier grouping to divide the set of correlated subchannels into subsets. Within each subset, a non-redundant constellation-specific unitary precoder is then designed to achieve maximum multipath diversity and coding gains. While greatly reducing the decoding complexity and simplifying the LCP design, subcarrier grouping offers optimal performance by maximizing multipath diversity and coding gains. In addition, the proposed system does not sacrifice the transmission rate. Analytic Evaluation and corroborating simulations reveal its performance merits.

  • space time block coded multiple access through frequency selective fading channels
    IEEE Transactions on Communications, 2001
    Co-Authors: Georgios B Giannakis
    Abstract:

    Mitigation of multipath fading effects and suppression of multiuser interference (MUI) constitute major challenges in the design of wide-band third-generation wireless mobile systems. Space-time (ST) coding offers an effective transmit-antenna diversity technique to combat fading, but most existing ST coding schemes assume flat fading channels that may not be valid for wide-band communications. Single-user ST coded orthogonal frequency-division multiplexing transmissions over frequency-selective channels suffer from finite-impulse response channel nulls (fades). Especially multiuser ST block-coded transmissions through (perhaps unknown) multipath present unique challenges in suppressing not only MUI but also intersymbol/chip interference. In this paper, we design ST multiuser transceivers suitable for coping with frequency-selective multipath channels (downlink or uplink). Relying on symbol blocking and a single-receive antenna, ST block codes are derived and MUI is eliminated without destroying the orthogonality of ST block codes. The system is shown capable of providing transmit diversity while guaranteeing symbol recovery in multiuser environments, regardless of unknown multipath. Unlike existing approaches, the mobile does not need to know the channel of other users. In addition to decoding simplicity, Analytic Evaluation and corroborating simulations reveal its flexibility and performance merits.